Tag: Chapter 18A

Chapter 18A is an enticing listing prospect for biotech firms in China, but they must first prove that their golden product is genuine and truly their own

O’Melveny, JunHe, MoFo, and Jingtian & Gongcheng aided TYK Medicines' USD74.3M debut on HKEX, the largest IPO under HK's Chapter 18A

Five law firms advised on Chinese biotechnology company Laekna’s HKD791 million chapter 18A offering, which is the largest such IPO to date this year

Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million